<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00157820</url>
  </required_header>
  <id_info>
    <org_study_id>SP-DATAS</org_study_id>
    <nct_id>NCT00157820</nct_id>
  </id_info>
  <brief_title>DATAS: The Dual Chamber &amp; Atrial Tachyarrhythmias Adverse Events Study</brief_title>
  <acronym>DATAS</acronym>
  <official_title>DATAS: The Dual Chamber &amp; Atrial Tachyarrhythmias Adverse Events Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Bakken Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Dual Chamber &amp; Atrial Tachyarrhythmias Adverse Events Study (DATAS) was designed to
      analyze the ability of dual chamber ICDs, to reduce clinically significant adverse events as
      compared to single chamber ICD in a non selected population with conventional indication of
      ICD implantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single chamber (SC) implantable cardioverter defibrillators (ICDs) have several limitations
      that might be relevant during follow up, like atrial pacing requirements, inadequate
      therapies, sustained atrial tachyarrhythmias and difficulties to achieve an accurate
      diagnosis of the arrhythmia. Dual chamber (DC) ICDs offer an attractive rationale solution,
      although controversy remains if the costs and complexity of the implants offer a real
      clinical advantage.

      The DATAS is a, prospective, multicentre, randomized, open labelled study, with three arms
      (two of them cross-over and the third parallels the other two)

      The primary objective of this trial is to determine whether use of Dual Chamber ICD
      (DDED-DDDR NASPE/BPEG Defibrillator/Pacemaker Codes) results in a significant decrease in the
      number of primary end points.

      The primary end point is a composite comprising four so-denominated &quot;Clinically Significant
      Adverse Events (CSAE)&quot;:

        1. all-cause mortality

        2. invasive intervention, hospitalization (&gt;24 h) or prolongation of hospitalization due to
           cardiovascular cause

        3. inappropriate shocks (two or more episodes with inappropriate shocks)

        4. sustained symptomatic atrial tachyarrhythmias that (a) require urgent termination or (b)
           last more than 48 h leading to therapeutic intervention.

      Secondary objectives are:

        1. Number of each of the components of the CSAE.

        2. Arrhythmia related: atrial tachyarrhythmia (AT), frequency and burden, ventricular
           tachyarrhythmia frequency and burden number of appropriate shocks, number of
           inappropriate shocks, need for reprogramming, need for medication/Radiofrequency
           Ablation (RFA) for arrhythmia control, pacemaker syndrome and development of dual
           chamber pacing indication.

        3. Cardiovascular related: New York Health Association (NYHA) functional class, exercise
           capacity, left ventricular ejection fraction (LVEF), reduction of medication
           (diuretics.).

        4. Quality of life: evaluated by the SF-36, Minnesota living test, with heart failure and
           Symptom Checklist instruments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2000</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CSAE-score Rate(Clinical Significant Adverse Events Score Rate)</measure>
    <time_frame>17 months</time_frame>
    <description>Main outcome was defined as the CSAE-score during follow-up: CSAE-score rate. We assigned death as the worst outcome during the entire study; and premature cross-over as the main failure of the assigned therapy. So each CSAE was assigned 1 point but (a) death was assigned a score equal to the max number of CSAE in any individual patient in the entire study +1, and (b) premature authorized crossover was given a score equal to the max number of CSAE in any individual patient in that period. Thus, main outcome was defined as the CSAE-score over length of follow-up resulting in a CSAE-score rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Each of the Components of the CSAE</measure>
    <time_frame>17 months</time_frame>
    <description>The primary endpoint is a composite of 5 pre-determine Clinical Significant Adverse Events (CSAE): (1) all-cause mortality, (2) invasive intervention due to Cardiovascular cause, (3) hospitalization (&gt;24h) or prolongation of hospitalization due to CV, (4) inappropriate shocks: two or more episodes with inappropriate shocks, (5) sustained symptomatic ATs that (a) require urgent termination or (b) lasted more than 48 h leading to therapeutic intervention.
Number of each of the components of CSAE, counts the number of events for each pre-determined level.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">354</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <condition>Ventricular Fibrillation</condition>
  <condition>Defibrillators, Implantable</condition>
  <arm_group>
    <arm_group_label>SC true</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single chamber Implantable Cardioverter Defibrillator programmed as a Single Chamber.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC sim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dual chamber ICD initially programmed as single chamber (SC simulated) ICD (''SC sim arm'')</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DC true</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dual chamber ICD initially programmed as a DDED (''DC true arm'').</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Single Chamber Implantable Cardioverter Defibrillator</intervention_name>
    <description>Single chamber ICD implantation: Medtronic GEM, Medtronic Marquis family of SC ICD</description>
    <arm_group_label>SC true</arm_group_label>
    <other_name>Medtronic GEM, Medtronic Marquis family of SC ICD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dual Chamber implantable cardioverter defibrilator</intervention_name>
    <description>Dual chamber ICD implantation: Jewel AF &amp; GemIII AT as DC ICDs (DC true and SC sim arms)</description>
    <arm_group_label>SC sim</arm_group_label>
    <arm_group_label>DC true</arm_group_label>
    <other_name>Medtronic Jewel AF, Medtronic GemIII AT, DC ICD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet the Class I implantation criteria for single chamber implantable cardioverter
             defibrillator according to the guidelines (ACC/AHA).

        Exclusion Criteria:

          -  Permanent atrial fibrillation

          -  Patients without structural heart disease

          -  Patient meets implantation criteria for dual-chamber pacing (symptomatic sinus node
             disease, all 2nd Atrio-Ventricular (AV) block [except asymptomatic Mobitz I] and all
             3rd degree AV block ).

          -  Patient with previous system implanted (ICD or pacemaker).

          -  Patients with biventricular stimulation or re-synchronization.

          -  Patient has a mechanical right heart valve.

          -  Patient has medical conditions that would preclude the testing required by the
             protocol, or limit study participation.

          -  Patient is unwilling or unable to cooperate or give written informed consent, or the
             patient is a minor and legal guardians refuse to give informed consent.

          -  Patient is or will be inaccessible for follow-up at the study center.

          -  Patients who are enrolled or planning to enroll in other clinical trials during the
             clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aurelio Quesada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario, Valencia, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jesus Almendral, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario Gregorio Mara√±on, Madrid, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando Arribas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario 12 de Octubre, Madrid, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Massimo Santini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Filippo Neri Hospital, Rome, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Wolpert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Mannheim, Mannheim, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pedro Adragao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Santa Cruz Hospital, Carnaxide, Portugal</affiliation>
  </overall_official>
  <reference>
    <citation>Quesada A, Almendral J, Arribas F, Ricci R, Wolpert C, Adragao P, Cobo E, Navarro X; DATAS Investigators. The DATAS rationale and design: a controlled, randomized trial to assess the clinical benefit of dual chamber (DDED) defibrillator. Europace. 2004 Mar;6(2):142-50.</citation>
    <PMID>15018874</PMID>
  </reference>
  <results_reference>
    <citation>Almendral J, Arribas F, Wolpert C, Ricci R, Adragao P, Cobo E, Navarro X, Quesada A; DATAS Steering Committee; DATAS Writing Committee; DATAS Investigators. Dual-chamber defibrillators reduce clinically significant adverse events compared with single-chamber devices: results from the DATAS (Dual chamber and Atrial Tachyarrhythmias Adverse events Study) trial. Europace. 2008 May;10(5):528-35. doi: 10.1093/europace/eun072. Epub 2008 Apr 7.</citation>
    <PMID>18390985</PMID>
  </results_reference>
  <results_reference>
    <citation>Ricci RP, Quesada A, Almendral J, Arribas F, Wolpert C, Adragao P, Zoni-Berisso M, Navarro X, DeSanto T, Grammatico A, Santini M; DATAS study Investigators. Dual-chamber implantable cardioverter defibrillators reduce clinical adverse events related to atrial fibrillation when compared with single-chamber defibrillators: a subanalysis of the DATAS trial. Europace. 2009 May;11(5):587-93. doi: 10.1093/europace/eup072.</citation>
    <PMID>19401341</PMID>
  </results_reference>
  <results_reference>
    <citation>Hadid C, Almendral J, Ortiz M, Schwab JO, Janko S, Mischke K, Arribas F, Wolpert C, Ricci R, Adragao P, Cobo E, Navarro X, Quesada A. Incidence, determinants, and prognostic implications of true pleomorphism of ventricular tachycardia in patients with implantable cardioverter-defribillators: a substudy of the DATAS Trial. Circ Arrhythm Electrophysiol. 2011 Feb;4(1):33-42. doi: 10.1161/CIRCEP.110.957068. Epub 2010 Nov 13.</citation>
    <PMID>21076160</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <results_first_submitted>March 10, 2011</results_first_submitted>
  <results_first_submitted_qc>July 17, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 21, 2012</results_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Defibrillators, Implantable</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Ventricular Tachyarrhythmias</keyword>
  <keyword>Clinical Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Ventricular Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were eligible if they met a standard Class I indication for a Single Chamber-Implantable Cardioverter Defibrillator (ICD) according to the 1998 ACC/AHA guidelines. Every patient eligible for ICD was screened at each study centre. Follow-up started immediately after randomization.</recruitment_details>
      <pre_assignment_details>The Dual chamber true (DC true) and Single chamber simulated (SC sim) arms crossed over after 8 months. All other crossovers were considered ‚Äòpremature crossovers‚Äô and had to be authorized by an independent Adverse Events Advisory Committee.
A 1-month wash out period was implemented after programmed crossover.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SC True</title>
          <description>Allocated to Single Chamber ICD (SC true arm) VVEV-VVI (NASPE/BPEG Defibrillator/Pacemaker Codes)</description>
        </group>
        <group group_id="P2">
          <title>SC Simulated Then DC True</title>
          <description>Dual chamber ICD initially programmed as Single Chamber ICD (simulated) then DC true programmed as Dual Chamber true (DDED-DDDR) NASPE/BPEG Defibrillator/Pacemaker Codes.</description>
        </group>
        <group group_id="P3">
          <title>DC True Then SC Sim</title>
          <description>Dual chamber ICD initially programmed as a DDED-DDDR (&quot;DC true arm&quot;) then programmed as Single Chamber simulated</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomized</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="116"/>
                <participants group_id="P3" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="111"/>
                <participants group_id="P3" count="112"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>1st 8 Month</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="111"/>
                <participants group_id="P3" count="112"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="99"/>
                <participants group_id="P3" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Premature cross-over</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>1 Month Wash Out Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="101">2 patients had crossed over prematurely in SC sim period, that are now carried to DC true period</participants>
                <participants group_id="P3" count="108">2 patients had crossed over prematurely in DC true period, that are now carried to SC sim period</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>2nd 8 Months</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="88"/>
                <participants group_id="P3" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Premature cross-over</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SC True</title>
          <description>Allocated to Single Chamber ICD (SC true arm) VVEV-VVI (NASPE/BPEG Defibrillator/Pacemaker Codes)</description>
        </group>
        <group group_id="B2">
          <title>SC Simulated Then DC True</title>
          <description>Dual chamber ICD initially programmed as Single Chamber ICD (simulated) then DC true programmed as Dual Chamber true (DDED-DDDR) NASPE/BPEG Defibrillator/Pacemaker Codes.</description>
        </group>
        <group group_id="B3">
          <title>DC True Then SC Sim</title>
          <description>Dual chamber ICD initially programmed as a DDED-DDDR (&quot;DC true arm&quot;) then programmed as Single Chamber simulated</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="111"/>
            <count group_id="B2" value="111"/>
            <count group_id="B3" value="112"/>
            <count group_id="B4" value="334"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="177"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="10"/>
                    <measurement group_id="B2" value="62" spread="11"/>
                    <measurement group_id="B3" value="66" spread="9"/>
                    <measurement group_id="B4" value="64" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="92"/>
                    <measurement group_id="B4" value="282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LVEF</title>
          <description>Left Ventricle Ejection Fraction (percentage)</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" spread="13"/>
                    <measurement group_id="B2" value="39" spread="14"/>
                    <measurement group_id="B3" value="34" spread="12"/>
                    <measurement group_id="B4" value="36" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>CSAE-score Rate(Clinical Significant Adverse Events Score Rate)</title>
        <description>Main outcome was defined as the CSAE-score during follow-up: CSAE-score rate. We assigned death as the worst outcome during the entire study; and premature cross-over as the main failure of the assigned therapy. So each CSAE was assigned 1 point but (a) death was assigned a score equal to the max number of CSAE in any individual patient in the entire study +1, and (b) premature authorized crossover was given a score equal to the max number of CSAE in any individual patient in that period. Thus, main outcome was defined as the CSAE-score over length of follow-up resulting in a CSAE-score rate.</description>
        <time_frame>17 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>SC True</title>
            <description>Allocated to Single Chamber ICD (SC true arm)</description>
          </group>
          <group group_id="O2">
            <title>SC Simulated</title>
            <description>Dual chamber ICD initially programmed as Single Chamber ICD (simulated)</description>
          </group>
          <group group_id="O3">
            <title>DC True</title>
            <description>Dual chamber ICD initially programmed as a DDED-DDDR (&quot;DC true arm&quot;</description>
          </group>
        </group_list>
        <measure>
          <title>CSAE-score Rate(Clinical Significant Adverse Events Score Rate)</title>
          <description>Main outcome was defined as the CSAE-score during follow-up: CSAE-score rate. We assigned death as the worst outcome during the entire study; and premature cross-over as the main failure of the assigned therapy. So each CSAE was assigned 1 point but (a) death was assigned a score equal to the max number of CSAE in any individual patient in the entire study +1, and (b) premature authorized crossover was given a score equal to the max number of CSAE in any individual patient in that period. Thus, main outcome was defined as the CSAE-score over length of follow-up resulting in a CSAE-score rate.</description>
          <population>ITT</population>
          <units>score/month</units>
          <param>Number</param>
          <units_analyzed>CSAE</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="223"/>
                <count group_id="O3" value="223"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>CSAE</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.112"/>
                    <measurement group_id="O2" value="0.128"/>
                    <measurement group_id="O3" value="0.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The assumed effect of the DC treatment was a reduction from 30 to 15% in the proportion of patients who develop a CSAE, as well as a 15% reduction in the mean of CSAE (from 6 to 5.1). The estimated sample size was 200 (DC true) vs. 100 (SC true) patients followed for 8 months, with a two-sided alfa &lt; 0.05 and a power of 88.8%.
The sample size was set up to 360 patients (120 patients per arm), considering losses in follow-up.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0028</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>0.67</ci_upper_limit>
            <estimate_desc>An additional primary analysis was pre-planned: the odds ratio of CSAE-score between DC and SC obtained from SAS GENMOD procedure with the length of follow-up as an ‚Äòoffset‚Äô.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Each of the Components of the CSAE</title>
        <description>The primary endpoint is a composite of 5 pre-determine Clinical Significant Adverse Events (CSAE): (1) all-cause mortality, (2) invasive intervention due to Cardiovascular cause, (3) hospitalization (&gt;24h) or prolongation of hospitalization due to CV, (4) inappropriate shocks: two or more episodes with inappropriate shocks, (5) sustained symptomatic ATs that (a) require urgent termination or (b) lasted more than 48 h leading to therapeutic intervention.
Number of each of the components of CSAE, counts the number of events for each pre-determined level.</description>
        <time_frame>17 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SC True</title>
            <description>Allocated to Single Chamber ICD (SC true arm)</description>
          </group>
          <group group_id="O2">
            <title>SC Simulated</title>
            <description>Dual chamber ICD initially programmed as Single Chamber ICD (simulated)</description>
          </group>
          <group group_id="O3">
            <title>DC True</title>
            <description>Dual chamber ICD initially programmed as a DDED-DDDR (&quot;DC true arm&quot;)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Each of the Components of the CSAE</title>
          <description>The primary endpoint is a composite of 5 pre-determine Clinical Significant Adverse Events (CSAE): (1) all-cause mortality, (2) invasive intervention due to Cardiovascular cause, (3) hospitalization (&gt;24h) or prolongation of hospitalization due to CV, (4) inappropriate shocks: two or more episodes with inappropriate shocks, (5) sustained symptomatic ATs that (a) require urgent termination or (b) lasted more than 48 h leading to therapeutic intervention.
Number of each of the components of CSAE, counts the number of events for each pre-determined level.</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="223"/>
                <count group_id="O3" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Invasive intervention CV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalizations (&gt;24h) or prolongued CV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inappropiate shocks (&gt;2 episodes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Long Duration AT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Duration of the enrollment+follow up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SC True</title>
          <description>Allocated to Single Chamber ICD (SC true arm)</description>
        </group>
        <group group_id="E2">
          <title>SC Simulated</title>
          <description>Dual chamber ICD initially programmed as Single Chamber ICD (simulated</description>
        </group>
        <group group_id="E3">
          <title>DC True</title>
          <description>Dual chamber ICD initially programmed as a DDED-DDDR (&quot;DC true arm&quot;)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Invasive interventions</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="111"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="223"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Hospitalization or prolongued hospitalizations</sub_title>
                <counts group_id="E1" events="42" subjects_affected="33" subjects_at_risk="111"/>
                <counts group_id="E2" events="51" subjects_affected="32" subjects_at_risk="223"/>
                <counts group_id="E3" events="47" subjects_affected="36" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="111"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="223"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Innapropiate shocks</sub_title>
                <counts group_id="E1" events="23" subjects_affected="10" subjects_at_risk="111"/>
                <counts group_id="E2" events="14" subjects_affected="7" subjects_at_risk="223"/>
                <counts group_id="E3" events="5" subjects_affected="2" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Sustain Symptomatic AT</sub_title>
                <description>sustained symptomatic ATs that (a) require urgent termination or (b) lasted more than 48 h leading to therapeutic intervention</description>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="223"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The follow-up might have been too short to reveal differences in heart failure-related hospitalizations and related mortality.
Premature crossovers are a limitation of RCT. However, our scoring system severely penalized this cross-overs.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr.A.Quesada</name_or_title>
      <organization>Hospital General Universitario de Valencia, Spain</organization>
      <email>aquesadad@secardiologia.es</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

